Loading stock data…
Nuvation Bio Inc (NUVB)
$6.42-0.07 (-1.08%)
Market ClosedLast close Jul 24
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvation Bio Inc. in the Healthcare sector is trading at $6.42 with a market capitalization of $1.8B. Wall Street consensus targets $12.33 (9 analysts), implying a +92.1% move over the next 12 months. The stock is currently 34% below its 52-week high of $9.75, remaining 14.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +92.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $83.23M↑ | $41.87M↑ | $13.12M↑ | $4.83M↑ | $3.08M |
| Gross Profit | $77.24M↑ | $40.59M↑ | $9.77M↑ | $2.26M↑ | $990,000 |
| Operating Income | $3.88M↑ | -$34.04M↑ | -$56.43M↑ | -$63.59M↓ | -$59.00M |
| Net Income | $5.40M↑ | -$36.59M↑ | -$55.79M↑ | -$59.01M↓ | -$53.24M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-45.69%
Volume
Today's trading volume
6.13M
Recent News
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says
Nuvation Bio's (NUVB) leadership showed "significant excitement" around the Safusidenib clinical pro
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug
According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview
Nuvation Bio Inc. (NYSE:NUVB) is one of the best small cap stocks to buy with the highest upside potential. RBC Capital lowered the price target on Nuvation Bio Inc. (NYSE:NUVB) to $19 from $20 on July 7 and reaffirmed an Outperform rating on the shares. The rating update came as part of a broader research note […]